Steroids from Carvone Promotor Prof
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Mint and Mint Oil Profile New York State Integrated Pest Management Cornell Cooperative Extension Program
http://hdl.handle.net/1813/56133 Mint and Mint Oil Profile New York State Integrated Pest Management Cornell Cooperative Extension Program Mint and Mint Oil Profile Active Ingredient Eligible for Minimum Risk Pesticide Use Brian P. Baker and Jennifer A. Grant New York State Integrated Pest Management, Cornell University, Geneva NY Label Display Names: Cornmint, Cornmint oil, U.S. EPA PC Code: 128800 (Peppermint is also Spearmint, Spearmint oil cross referenced under the listing for mint and mint oil) Active Components: Carvone, Menthol, pulegone, limonene, linarin, pinene, piperitone, linalool, and CA DPR Chem Code: Not Found various other terpenoids, alcohols, esters, and hydrocarbons Other Names: Cornmint oil, spearmint oil, men- thol oil, spearmint terpenes CAS Registry #s: 8008-79-5 (Spearmint oil) Other Codes: 68917-18-0 (Cornmint oil) Cornmint oil—FEMA: 4219; EINECS: 290-058-5; HT: None (Cornmint and Spearmint) 3301.25 Spearmint oil—FEMA: 3032; EINECS: 283-656- HT: 3301.25; RTECS: WG7360000 Summary: Mint and mint oils are a class of active ingredients derived from selected members of the plant genus Mentha. Primary sources include cornmint, peppermint, and spearmint. Active substances contained in the plants and essential oils in this class include menthol, carvone, and various other ter- penoids. Peppermint and spearmint are commonly used food ingredients; cornmint is used as a food ingredient in some Asian cuisines and is a major source of food-grade menthol used as a flavoring agent. As a pesticide, mint and mint oils work primarily through non-toxic modes of action as repellents, but also have anti-microbial properties. Peppermint is covered in a separate profile. -
IJCB 42B(1) 166-172.Pdf
Indian Journal of Chemistry Vol. 42B, January 2003, pp. 166-172 Synthesis and biological activity of 16-arylidene derivatives of estrone and estrone methyl ether Maninder Minu* & Dharam Paul lindal University In 5titutc of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India and G Leclercq & M Borras institut Jules Bordet, Association Hospitaliere de Bruxelles. Centre des Tumeurs de I'ULB, Rue Heger-Bordet 1- 1000, Belgiulll Received 24 April 200 I .. accepted (revised) 20 March 2002 The synthesis of 16-arylidene derivatives 3, 4, S, 6, 7. 8. 9, 10, 11, 12, 13, 14 and IS is described. These compounds have been tested at NCI, Bethesda, for their antineoplastic acti vity against the cell panel consisting of 60-ce!l lines and th e compounds 3, 4, S, 6 and 7 have also been tested for their ill vitro estrogenic / antiestrogenic activity; induction of ERE dependent luciferase inductio n was measured (MvLN celis). The formation of active steroids by aromatase has It was conceived that selective inhibitors of aroma been considered to play an important role in the de tase might be useful as a pharmacological tool to de velopment of human breast carcinoma t, at least one vice successful treatment approach for the hormonal third of all breast cancers establishing that. the estro dependent breast cancer. Our efforts were focused on gen-dependent carcinoma regresses following estro designing estrogen and estrogen methyl ether deriva 2 gen deprivation . In the postmenopausal women, the tives that might inhibit or possess antiestrogenic activ production of estrogen takes place in peripheral tissue ity. From these efforts, several 16-arylidine deriva 3 from inactive precursors by the action of aromatase . -
Part I Biopharmaceuticals
1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays -
EURL GUIDANCE on SUBSTANCES INCLUDED in the SUBSTANCE CATEGORIES LISTED in ANNEX I of SANTE 2017/11987
DRAFT 24 September 2019 (EURLs ANSES, BVL and WFSR) EURL GUIDANCE ON SUBSTANCES INCLUDED IN THE SUBSTANCE CATEGORIES LISTED IN ANNEX I of SANTE 2017/11987 1. A1a Stilbenes (EURL WFSR Wageningen) Cfr. Substances listed for Group A1 in the MMPR Guidance 2. A1b Antithyroid agents (EURL WFSR Wageningen) Cfr. Substances listed for Group A2 in the MMPR Guidance 3. A1c Steroids (EURL WFSR Wageningen) Cfr. Substances listed for Group A3 in the MMPR Guidance 17b-Testosterone (4-Androsten-17b-ol-3-one) 17a-Testosterone (4-Androsten-17a-ol-3-one) 17a-Boldenone 17b-Boldenone Clostebol (CLTb) (4-androsten-4-chloro-17ß-ol-3-one) CLAD (4-chloro-4-androst-3,17-dione) (chloorandrosteendion) a-Estradiol (17a-Estradiol) 17b-estradiol (17ß-estradiol) Methylboldenone (1,4-Androstadien-17a-methyl-17b-ol-3-one) 17a-Methyltestosterone (4-Androsten-17a-methyl-17b-ol-3-one) 17b-Nortestosterone (b-nandrolone) 17α-Nortestosterone (4-estren-17a-ol-3-one) Ethinylestradiol (EE2) 17a-Trenbolone 17b-Trenbolone 16b-hydroxy-stanozolol Megestrol Melengestrol Chlormadinone Medroxyprogesterone Progesterone (P1) (4-Pregnene-3,20-dione (Pregnen(4)-3,20-dione)) Androsten-17ß-ol-3-one [1,(5a)-] (17b-1-testosteron) Mestranol (Ethynylestradiol 3-methyl ether) Fluoxymesterone (FMT) (4-androsten-9a-fluoro-17a-methyl-11ß,17ß-diol-3-one) DHEA (5-androsten-3b-ol-17-one) ethyl-5ß-estrane-3a,17ß-diol [17α-] (EED) Exemestane (6-Methyleneandrosta-1,4-diene-3,17-dione) Mesterolone (Androviron) Dromostanolone (Drostanolone) 2a-Methyl-5a-androstan-3a-ol-17-one -
United States Patent Of?Ce 3,409,643 Patented Nov
i United States Patent Of?ce 3,409,643 Patented Nov. 5, 1968 l 2 ’ 3,409,643 choire when preparing esters atI C-17 of l7a-alkynyl-l7? PROCESS FOR THE PREPARATION OF 1711 hydroxy steroids and particularly ' ALKYNL -l7?-ALKANOYLOXY STEROIDS of those steroids which OF THE ANDROSTANE AND ESTRANE also possess functions or systems ,(e.g. 3-methoxy-A2'5(1°> SERIES , and 3-ethoxy-A3,5.-) which are highly reactive or sensitive Elliot L. Shapiro, Cedar Grove, N.J., assignor to Schering Corporation, Bloom?eld, N.J., a corporation of New hydroxyl group. Thus, Jersey preparation of 3-methoxy-17a-ethinyl-2,5(10)-esteradien . No Drawing. Filed Mar. 11, 1966, Ser. No. 533,435 17,8-01 l7_-aeetate (an intermediate in the preparation of 10 Claims. (Cl. 260-—397.5) therapeutically valuable l9-n0r steroids) via methods 10 \ known in the art involves reacting 3-methoxy-l7a-ethinyl 2,5 ( 10)-estradien-17B-ol withv acetic anhydride in pyridine ' _ABSTRACT OF THE DISCLOSURE at elevated temperatures or with acetyl chloride in pyri A novel process for the preparation of 17a-alkynyl dine. Both the aforementioned reaction mediums cause l7?-alkanoyloxy steroids of the androstane and estrane ' involving destruction of the existing series comprises subjecting a 17~keto steroid of the andro A-ring sys em such as conversion of the 3-methoxy stane and estrane series to the ' ' Azimol- sys‘em to a 3-keto-l9-nor-A4- system or to an acetylide and adding in situ to the 17a-alkynyl-l7B-hy aromatic A-ring system (i.e. -
Labeling and Synthesis of Estrogens and Their Metabolites
Labeling and Synthesis of Estrogens and Their Metabolites Paula Kiuru University of Helsinki Faculty of Science Department of Chemistry Laboratory of Organic Chemistry P.O. Box 55, 00014 University of Helsinki, Finland ACADEMIC DISSERTATION To be presented with the permission of the Faculty of Science of the University of Helsinki, for public criticism in Auditorium A110 of the Department of Chemistry, A. I. Virtasen Aukio 1, Helsinki, on June 18th, 2005 at 12 o'clock noon Helsinki 2005 ISBN 952-91-8812-9 (paperback) ISBN 952-10-2507-7 (PDF) Helsinki 2005 Valopaino Oy. 1 ABSTRACT 3 ACKNOWLEDGMENTS 4 LIST OF ORIGINAL PUBLICATIONS 5 LIST OF ABBREVIATIONS 6 1. INTRODUCTION 7 1.1 Nomenclature of estrogens 8 1.2 Estrogen biosynthesis 10 1.3 Estrogen metabolism and cancer 10 1.3.1 Estrogen metabolism 11 1.3.2 Ratio of 2-hydroxylation and 16α-hydroxylation 12 1.3.3 4-Hydroxyestrogens and cancer 12 1.3.4 2-Methoxyestradiol 13 1.4 Structural and quantitative analysis of estrogens 13 1.4.1 Structural elucidation 13 1.4.2 Analytical techniques 15 1.4.2.1 GC/MS 16 1.4.2.2 LC/MS 17 1.4.2.3 Immunoassays 18 1.4.3 Deuterium labeled internal standards for GC/MS and LC/MS 19 1.4.4 Isotopic purity 20 1.5 Labeling of estrogens with isotopes of hydrogen 20 1.5.1 Deuterium-labeling 21 1.5.1.1 Mineral acid catalysts 21 1.5.1.2 CF3COOD as deuterating reagent 22 1.5.1.3 Base-catalyzed deuterations 24 1.5.1.4 Transition metal-catalyzed deuterations 25 1.5.1.5 Deuteration without catalyst 27 1.5.1.6 Halogen-deuterium exchange 27 1.5.1.7 Multistep labelings 28 1.5.1.8 Summary of deuterations 30 1.5.2 Enhancement of deuteration 30 1.5.2.1 Microwave irradiation 30 1.5.2.2 Ultrasound 31 1.5.3 Tritium labeling 32 1.6 Deuteration estrogen fatty acid esters 34 1.7 Synthesis of 2-methoxyestradiol 35 1.7.1 Halogenation 35 1.7.2 Nitration of estrogens 37 1.7.3 Formylation 38 1.7.4 Fries rearrangement 39 1.7.5 Other syntheses of 2-methoxyestradiol 39 1.7.6 Synthesis of 4-methoxyestrone 40 1.8 Synthesis of 2- and 4-hydroxyestrogens 41 2. -
United States Patent Patented Dec
Mice 3,293,301 United States Patent Patented Dec. 20, 1966 1 2 tional acid per mole of carvoxime at the beginning of the 3,293,301 hydrolysis. Phosphoric acid is the preferred additional PREPARATION OF CARVONE acid. John M. Derfer, Jacksonville, Bernard J. Kane, Atlantic Also, by using an acceptor for the hydroxylamine it is Beach, and Donald G. Young, Jacksonville, Fla., as not necessary to remove the carvone during the hydrolysis signors to The Glidden Company, Cleveland, Ohio, a as in Reitsema, since there is an equilibrium between corporation of Ohio No Drawing. Filed Apr. 7, 1964, Ser. No. 358,051 carvoxime and its hydrolysis products, carvone and hy- ' 13 Claims. (Cl. 260-—-587) droxylamine, and the reaction can be carried to comple tion before any recovery of the carvone is required. The present invention relates to the preparation of We have found that the objects of the invention can be carvone. achieved when the reactions are carried ‘out in a suitable 'Carvone is an important constituent of many essential solvent such as a lower aliphatic alkanol. The preferred oils. About 65% of spearmint oil is l-carvone and d solvent is isopropyl alcohol. But any other solvent for carvone is the chief constituent of caraway and dill seed carvoxime and carvone which is water soluble, nonreac oils. 15 tive with the reacting materials, and which has a boiling The preparation of l-carvone from d-limonene has been point of at least about 75° C, or higher can be used. described by Bordenca et al., Ind. and Eng. -
Biomarker Development to Assess Bone Health
Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author. Biomarker development to assess bone health A thesis presented in partial fulfilment of the requirements for the degree of Doctor of Philosophy in Nutritional Science at Massey University, Palmerston North, New Zealand. Diana Leticia Cabrera Amaro 2019 Abstract Postmenopausal women experience an accelerated bone loss with increased fracture risk caused by oestrogen deficiency. Biomarkers of bone turnover assess the changes of bone metabolism in postmenopausal women; however, prediction of bone loss with these common biomarkers cannot be achieved because bone biomarkers might not reflect the bone microenvironment status. Thus, there is a need for discovering new bone biomarkers that can efficiently predict bone loss in postmenopausal women. Previous studies suggest that the ovariectomised sheep in combination with injected glucocorticoids may be a reliable model to evaluate the biological response to oestrogen withdrawal as well as the bone remodelling process. The purpose of this research programme was to test the following hypotheses: 1) ovariectomising sheep in combination with monthly injections of glucocorticoids would result in decreased bone mineral density (BMD) and increased plasma bone remodelling marker concentration over a shorter period of time; 2) the plasma metabolome and lipidome of ovariectomised sheep would be different, and the biochemical changes in plasma and bone remodelling would be associated with bone loss; 3) and finally, there would also be a difference in the plasma metabolome and lipidome of Singaporean–Chinese postmenopausal women according to their bone mineral density status. -
Biochem Press
Internet Electronic Journal of Molecular Design 2003, 2, 435–453 ISSN 1538–6414 BioChem Press http://www.biochempress.com Internet Electronic Journal of Molecular Design July 2003, Volume 2, Number 7, Pages 435–453 Editor: Ovidiu Ivanciuc Special issue dedicated to Professor Nenad Trinajstiü on the occasion of the 65th birthday Part 1 Guest Editors: Douglas J. Klein and Sonja Nikoliü Using Simulated 2D 13C NMR Nearest Neighbor Connectivity Spectral Data Patterns to Model a Diverse Set of Estrogens Richard D. Beger, Kathleen J. Holm, Dan A. Buzatu, and Jon G. Wilkes Division of Chemistry, National Center for Toxicological Research, Food and Drug Administration, Jefferson, AR 72079 Received: March 21, 2003; Revised: May 2, 2003; Accepted: May 7, 2003; Published: July 31, 2003 Citation of the article: R. D. Beger, K. J. Holm, D. A. Buzatu, and J. G. Wilkes, Using Simulated 2D 13C NMR Nearest Neighbor Connectivity Spectral Data Patterns to Model a Diverse Set of Estrogens, Internet Electron. J. Mol. Des. 2003, 2, 435–453, http://www.biochempress.com. Copyright © 2003 BioChem Press R. D. Beger, K. J. Holm, D. A. Buzatu, and J. G. Wilkes Internet Electronic Journal of Molecular Design 2003, 2, 435–453 Internet Electronic Journal BioChem Press of Molecular Design http://www.biochempress.com Using Simulated 2D 13C NMR Nearest Neighbor Connectivity Spectral Data Patterns to Model a Diverse Set of Estrogens# Richard D. Beger,* Kathleen J. Holm, Dan A. Buzatu, and Jon G. Wilkes Division of Chemistry, National Center for Toxicological Research, Food and Drug Administration, Jefferson, AR 72079 Received: March 21, 2003; Revised: May 2, 2003; Accepted: May 7, 2003; Published: July 31, 2003 Internet Electron. -
United States Patent Office
- 2,837,570 United States Patent Office Patented June 3, 1958 2 thesis of l-carvone from d-limonene glycol are repre sented as follows, along with the structural formulae of 2,837,570 l-carvone, d-limonene and d-limonene monoxide. For purposes of illustration, the intermediate substitution METHOD OF PREPARNG CARVONE 5 product formed in the dehydration and hydrolysis of the Seymour M. Linder, Eggertsville, and Frank P. Green 1-hydroxyhydrocarvone is represented as the semicar span, Buffalo, N.Y., assignors to Food Machinery and . bazone derivative of that compound. Chemical Corporation, San Jose, Calif. (His GH, CE No Drawing. Application March 21, 1956 -o COH Serial No. 572,789 10 6 Claims. (C. 260-587) Hic bH, C bH, NHMC NH/ 5 This invention relates to a method for preparing 1-car S n vone, and particularly to a method for preparing 1-car C /'sCH HC /o CH vone from d-limonene and certain d-limonene deriva : - d-limonene monoxide d-limonene glycol - tives. (H, CH 1-Carvone, the levoratory form of carvone, by reason COE O of its minty odor and flavor has found wide acceptance 20 / in the prepartion of cosmetics and comestibles. Typi HaC Yo-NNENH cally, it is used as a flavoring and perfuming ingredient for toothpaste, mouth wash, chewing gum and mint can dies. 1-Carvone is expensive, presently being obtained 25 from principally from spearmint oil in which it occurs / Sn naturally. HC CH The high cost combined with the usefulness of 1-car -carvone vone offers a strong incentive to chemists to devise syn thetic methods for preparing the material. -
Structure-Activity Relationships for a Large Diverse Set of Natural, Synthetic, and Environmental Estrogens
280 Chem. Res. Toxicol. 2001, 14, 280-294 Structure-Activity Relationships for a Large Diverse Set of Natural, Synthetic, and Environmental Estrogens Hong Fang,† Weida Tong,*,† Leming M. Shi,†,‡ Robert Blair,§ Roger Perkins,† William Branham,§ Bruce S. Hass,§ Qian Xie,† Stacy L. Dial,§ Carrie L. Moland,§ and Daniel M. Sheehan§ R.O.W. Sciences, Inc., 3900 NCTR Road, MC 910, Jefferson, Arkansas 72079, and Division of Genetic and Reproductive Toxicology, National Center for Toxicological Research, Jefferson, Arkansas 72079 Received October 3, 2000 Understanding structural requirements for a chemical to exhibit estrogen receptor (ER) binding has been important in various fields. This knowledge has been directly and indirectly applied to design drugs for human estrogen replacement therapy, and to identify estrogenic endocrine disruptors. This paper reports structure-activity relationships (SARs) based on a total of 230 chemicals, including both natural and xenoestrogens. Activities were generated using a validated ER competitive binding assay, which covers a 106-fold range. This study is focused on identification of structural commonalities among diverse ER ligands. It provides an overall picture of how xenoestrogens structurally resemble endogenous 17â-estradiol (E2) and the synthetic estrogen diethylstilbestrol (DES). On the basis of SAR analysis, five distinguishing criteria were found to be essential for xenoestrogen activity, using E2 as a template: (1) H-bonding ability of the phenolic ring mimicking the 3-OH, (2) H-bond donor mimicking the17â-OH and O-O distance between 3- and 17â-OH, (3) precise steric hydrophobic centers mimicking steric 7R- and 11â-substituents, (4) hydrophobicity, and (5) a ring structure. The 3-position H-bonding ability of phenols is a significant requirement for ER binding. -
Alternative Solvents in Carvone Hydrogenation
Catarina Isabel Cabral de Carvalho e Melo Mestrado Integrado em Engenharia Química e Bioquímica Alternative Solvents in Carvone Hydrogenation Dissertação para obtenção do Grau de Mestre em Engenharia Química e Bioquimica Orientadora: Dra Ewa Bogel-Łukasik Júri: Presidente: Prof. Doutor Manuel Nunes da Ponte Arguente: Doutor Rafał Marcin Bogel-Łukasik Vogal: Doutora Ewa Bogel-Łukasik Julho de 2011 Copyright Os direitos de cópia da dissertação intitulada de “Alternative Solvents in Carvone Hydrogenation” pertencem ao autor, à Faculdade de Ciências e Tecnologia e à Universidade Nova de Lisboa. A Faculdade de Ciências e Tecnologia e a Universidade Nova de Lisboa têm o direito, perpétuo e sem limites geográficos, de arquivar e publicar esta dissertação através de exemplares impressos reproduzidos em papel ou de forma digital, ou por qualguer outro meio conhecido ou que venha a ser inventado, e de a divulgar através de repositórios científicos e de admitir a sua cópia e distrilbuição com objectivos educacionais ou de investigação, não comerciais, desde que seja dado crédito ao autor e editor. ii Acknowledgments The accomplishment of this thesis was only possible due to the contribution of several people, to whom I would like to thank. First I would like to express my gratitude to my supervisor Dr. Ewa Bogel Łukasik for the ‐ supervision and all her help, and to Professor Dr. Manuel Nunes da Ponte, head of Chemical Engineering Department where I have had the opportunity to work. I would like to acknowledge Professor Dr. Marco Silva for all the help provided in order to make get along with the Gas Chromatograph.